What most fail to see here....
Sarepta enrolled the older boys that you would expect a decline fast....but they have improved ....
Gsk/Prosensa enrolled the youngest possible but may have screwed up doing this.....
walk test would mean little because the younger you are with dmd you can walk anyway.
the dystrophin also that they produced more than likely cannot be used as marker if it is all over the place .
next long term safety issues with that older second generation antisense is well known. I would think that older antisense would only be good for short term uses.
IF AVAILABLE OR IF UNDER BUYOUT TALKS?
Morgan Stanley Global Healthcare Conference in New York, NY on Monday, September 9, 2013 at 1:50 p.m. Eastern Time.
R.W. Baird 2013 Healthcare Conference in New York, NY on Wednesday, September 11, 2013 at 10:50 a.m. Eastern Time.
Will have many drug platforms the will change medicines for the better and create drugs that does not cause of target effects the gives so many side effects.
Robert W Baird and Co Health Care Conference
If in any way Sarepta has any news it will be released before this conference.
Our RNA-based technologies and PMO-X™, PMOplus™ and PPMO chemistries combine to make a versatile, collaboration-ready, therapeutics research and development platform with broad applicability. Our platform has demonstrated utility across multiple therapeutic categories, including the promise of potentially transformative, safe and effective treatment options for rare and infectious diseases.
In addition to offering our collaboration-ready RNA-based technology platform, we have multiple program opportunities available for partnering, including our clinical stage Duchenne muscular dystrophy program and several anti-infective and rare disease programs.
Beyond strategic partnerships with industry, Sarepta also maintains a continuing interest in establishing research-advancing collaborative agreements with select academic, governmental and non-governmental organizations.
dis you guys catch that................................................................................................
selling yesterday was fund selling,gild was also down and a few others.....was not per say long term holders. I look for many more long term holders to pick up Sarepta shares going forward.
this will change our 52 week high/low on oct 3 2013
Has nothing to do with any post anyone has.None of us could move this stock either way unless we discovered breaking news.We are here for knowledge and entertainment for the sharing on this good future company.
The 96 week data will be released at that time and with that we may see something new like'' some muscle mass repair starting to appear or something alike''